Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.50 |
| ▸ | MC5R | P33032 | 10/20 | 0.50 |
| ▸ | MC3R | P41968 | 10/20 | 0.50 |
| ▸ | MC1R | Q01726 | 10/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.48 |
| ▸ | ITGAV | P06756 | 7/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075671 | 0.98 | MC4R (0.50) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL14075646 | 0.94 | ITGB3 (0.46) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL14262356 | 0.92 | MC4R (0.43) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL14075664 | 0.91 | ITGB3 (0.51) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL14075719 | 0.90 | ITGB3 (0.54) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL14075705 | 0.90 | ITGB3 (0.53) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL14075702 | 0.88 | MC4R (0.44) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL12808284 | 0.88 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL21475019 | 0.88 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL7743533 | 0.88 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213175-A1 | Click chemistry-derived cyclic peptidomimetics as integrin markers | ITGB1, ITGAM, ITGB3 | MC4R 317/4885MC5R 660/4885MC3R 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.